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We have obtained a vaccinia virus recombinant which contains a complete cDNA copy of the 26S RNA of
Sindbis virus within the thymidine kinase gene of the vaccinia virus genome. This recombinant constitutively
transcribed the Sindbis sequences throughout the infectious cycle, reflecting the dual early-late vaccinia
promoter used in this construction. The Sindbis-derived transcripts were translationally active, giving rise to
both precursor and mature structural proteins of Sindbis virus, including the capsid protein (C), the precursor
of glycoprotein E2 (PE2), and the two mature envelope glycoproteins (El and E2). These are the same products
translated from the 26S mRNA during Sindbis infection, and thus these proteins were apparently cleaved,
glycosylated, and transported in a manner analogous to that seen during authentic Sindbis infections. By using
epitope-specific antibodies, it was possible to demonstrate that recombinant-derived proteins were incorporated
into Sindbis virions during coinfections with monoclonal antibody-resistant Sindbis variants. These results
suggest that all the information necessary to specify the proper biogenesis of Sindbis virus structural proteins
resides within the 26S sequences and that vaccinia may provide an appropriate system for using DNA molecular
genetic manipulations to unravel a variety of questions pertinent to RNA virus replication.
Vaccinia virus, a poxvirus (reviewed in reference 30), has
a number of advantages for use as a eucaryotic expression
vector. These include the broad host range of the virus,
which allows genetic information to be shuttled among a
variety of species and cell types; the size of the vaccinia
virion and its DNA genome, which accommodates large or
multiple foreign inserts (or both) in an infectious virus (47);
high-titered stocks of infectious recombinant virus that en-
able virtually 100% of a cell population to be synchronously
infected and to express the foreign gene; the absence of
splicing during RNA maturation and cytoplasmic localiza-
tion of vaccinia gene expression (mediated largely by viral
enzymes), that allows proper expression of foreign inserts
lacking introns or proper transport signals; and finally, the
fact that vaccinia is a relatively safe vaccine strain. By using
in vivo marker rescue techniques (18, 32, 57), these at-
tributes have been used in several laboratories to construct a
number of recombinants that express influenza hemaggluti-
nin (33, 47), hepatitis B surface antigen (35, 46), herpesvirus
thymidine kinase (25, 34) and glycoprotein D antigen (35),
the malaria circumsporozoite antigen (45), the rabies virus
glycoprotein (21), and the vesicular stomatitis virus G and N
proteins (27). Such recombinants may prove useful in the
prevention of a variety of human diseases (31, 35, 47), but
such applications await further research into vaccinia virus
pathogenesis and possible vaccination side effects.
Here we report initial studies on the use of vaccinia as an
expression vector to study the production of Sindbis virus-
specific proteins and RNA transcripts derived from cloned
cDNA. Sindbis virus is the prototype of the alphavirus genus
of the family Togaviridae. Alphaviruses replicate in the
cytoplasm and contain a single-stranded RNA genome with
plus strand polarity (reviewed in reference 52). Two species
of viral mRNA are found in Sindbis-infected cells: 49S RNA,
* Corresponding author.
which is packaged into mature virions as well as serving as
message for the nonstructural proteins, and 26S RNA, which
encodes the structural polypeptides. In vivo, the 26S RNA is
translated into a 130,000-molecular-weight polyprotein
(130K polyprotein) which is cotranslationally cleaved and
processed into the capsid protein, C, and two glycosylated
membrane proteins, El and E2 (37; reviewed in reference
39). The following study describes our efforts to produce the
Sindbis proteins translated from 26S RNA by using a vac-
cinia virus vector and to assess the utility of this expression
system for investigating basic questions in alphavirus biol-
ogy.
MATERIALS AND METHODS
Cells, virus, and infections. Vaccinia virus (WR strain) was
propagated and titrated as previously described (15). Sindbis
virus (HR small plaque strain; or SIN V33/50/23; see below)
was grown and titrated with either BHK-21 or primary
chicken embryo fibroblast (36) cells. BSC-40 cells, TK- L
cells (LTK- cells) (14), Chinese hamster ovary (CHO) cells,
MDBK cells, and BHK-21 cells (American Type Culture
Collection) were maintained at 37°C under 5% CO2 in Eagle
minimum essential medium (Flow Laboratories) supple-
mented with 10% heat-inactivated fetal calf serum, 2 mM
L-glutamine, and 10 ,ug of gentamicin sulfate per ml. Unless
otherwise specified, virus infections and radioactive labeling
procedures were carried out precisely as previously
described (15).
Recombinant DNA. Plasmid DNA manipulations were
carried out essentially as summarized by Maniatis et al. (28).
Restriction enzymes, T4 DNA ligase, T4 polynucleotide
kinase, and Escherichia coli DNA polymerase I were pur-
chased from New England Biolabs; Klenow fragment was
purchased from Bethesda Research Laboratories; and calf
intestinal alkaline phosphatase was purchased from Boeh-
ringer Mannheim Biochemicals. Details of the plasmid con-
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structions are found below and in the legend to Fig. 1. E. coli
MC1061 (5) was modified by P1 transduction (from strain
C600; tnJO, recA56) to tetracycline resistance and a UV-
sensitive phenotype (probably recA56) and used to propa-
gate recombinant plasmids.
DNA transfection and marker rescue. A 5-p.g portion of
cesium chloride-purified pVV3S DNA was coprecipitated
with 1 pug of wild-type vaccinia DNA (to facilitate marker
rescue) and 15 p.g of carrier salmon sperm DNA by using the
calcium phosphate technique (12). The DNA precipitates
were added to monolayers of LTK- cells (without bromo-
deoxyuridine selection) which had been infected with wild-
type vaccinia at a multiplicity of 0.05 PFU per cell 3 h
previously. After 4 h, the cells were washed with serum-free
medium and shocked for 40 s with 15% glycerol in HEPES
(N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid)-
buffered saline (pH 7.1) (24) to facilitate DNA uptake;
normal medium was added, and the infected or transfected
monolayers were incubated at 37°C for 72 h. The progeny
virions from this initial marker rescue step were harvested
and titrated. TK- virus, including potential recombinants,
was amplified by low-multiplicity passage through LTK-
cells in the presence of 25 jig of bromodeoxyuridine per ml.
The TK- vaccinia virus present in the amplified crude stock
was then screened for recombinants containing the Sindbis-
specific insert of interest by using the nitrocellulose in situ
plaque hybridization procedure described by Villarreal and
Berg (56). Recombinants of interest were subjected to at
least two rounds of plaque purification until 100% of the
plaques scored as positive with appropriate radioactive
probes.
DNA analyses. To obtain vaccinia DNA, 100-mm dishes of
BSC-40 cells were infected with vaccinia virus at a multi-
plicity of 10 PFU per cell for 24 h. The infected cells were
harvested, suspended in 600 pl1 of phosphate-buffered saline
(PBS), and freeze-thawed three times. The crude extract was
adjusted to 0.5% Triton X-100, 35 mM ,B-mercaptoethanol,
and 20 mM EDTA, transferred to a 1.5-ml microfuge tube,
and centrifuged in a Tomy microfuge (model RC-15A) at
3,000 rpm and 25°C for 2.5 min to pellet the cell nuclei. The
supernatant was transferred to a fresh tube and centrifuged
at 15,000 rpm and 25°C for 10 min to pellet virus core
particles. The pellet was suspended in 100 p.l of 10 mM Tris
hydrochloride (pH 8)-i mM EDTA-5 mM P-
mercaptoethanol-proteinase K (150 Rg/ml)-200 mM
NaCl-1% sodium dodecyl sulfate (SDS) and incubated at
50°C for 30 min. After this digestion, the supernatant was
twice extracted with Tris-EDTA buffer (10 mM Tris [pH
7.5], 1 mM EDTA), saturated with phenol-chloroform-
isoamyl alcohol (25:24:1), and ethanol precipitated. The
DNA was pelleted at 15,000 rpm and 4°C for 1 min, air dried,
and suspended in 25 ,ul of Tris-EDTA buffer. Approximately
10 to 20 ,ug of vaccinia DNA was obtained per dish. The
DNA was digested with restriction endonucleases under the
conditions suggested by the manufacturer (Bethesda Re-
search Laboratories of New England Biolabs). The digests
were electrophoresed in 0.7% agarose (Seakem) gels at 40 V
for 12 h in Tris-acetate buffer (42). The DNA bands were
visualized by staining with 0.5 p.g of ethidium bromide per ml
and photographed with a Polaroid MP-4 camera set-up. The
DNA was then blotted onto nitrocellulose and hybridized
with appropriate nick-translated probes (49).
RNA analyses. BSC-40 cells were infected for 5 h in the
presence of 100 p.g of cycloheximide to amplify early mRNA
sequences. Total infected cell RNA was extracted and
purified either by the cesium chloride-Sarkosyl method (11)
or by isolation of total nucleic acids followed by digestion
with DNase I (54). Total RNA was fractionated into
poly(A)- and poly(A)+ fractions with oligo(dT)-cellulose
(Collaborative Research, T-3 grade) column chromatogra-
phy (17). The sizes of the Sindbis-specific transcripts were
measured by Northern blotting of the RNA from denaturing
formaldehyde gels (28). In SI-nuclease protection studies (2,
7), probes were 5' end labeled with [-y-32P]ATP (ICN Phar-
maceuticals, Inc.) and T4 polynucleotide kinase (New Eng-
land Biolabs). Annealing conditions and nuclease Si (PL
Biochemicals) concentrations were optimized empirically;
both duplex DNAs (10 ,ug/ml) and denatured carrier DNAs
(20 ,ug/ml) were included during Si digestion.
Protein synthesis. Monolayers of infected BSC-40 cells in
60-mm dishes were labeled with 5 to 25 p.Ci of
[35S]methionine (1,200 Ci/mM; New England Nuclear Corp.)
per ml according to the protocols detailed in the figure
legends. The radioactive medium was removed, and the
infected monolayers were rinsed gently three times with
ice-cold PBS. The cell monolayers were solubilized in 1 ml
of 0.5% SDS containing 20 p.g of phenylmethylsulfonyl
fluoride to inhibit proteases. The extract was pipetted up and
down vigorously to shear cellular DNA, frozen and thawed
once, sonicated six times for 10 s each, and heated at 90°C
for 10 min. Appropriate volumes of extract (50 to 100 ,ul)
were diluted to 1 ml with RIPA buffer (1% [wt/vol] sodium
deoxycholate, 1% [vol/vol] Triton X-100, 0.2% [wt/vol] SDS,
150 mM NaCl, 50 mM Tris hydrochloride [pH 7.4]) and
mixed with 3 to 5 p.l of antiserum; 200 p.l of 10% (vol/vol)
protein A-Sepharose CL4B beads (Pharmacia Fine Chemi-
cals) in RIPA buffer were added, and the mixtures were
gently agitated at 4°C for 1 to 12 h. The beads were then
pelleted and washed three times with ice-cold RIPA buffer.
The immune complexes bound to the beads were released by
adding 50 p.l of SDS-polyacrylamide gel electrophoresis
sample buffer and heating at 100°C for 3 min. The beads were
pelleted in a microfuge, and the supernatants were electro-
phoresed on 10.8% discontinuous SDS-polyacrylamide gels
(53). The gels were then impregnated with 2, 5-diphenyloxa-
zole (3) and exposed on Kodak XAR-5 film at -70°C. The
antisera used in these experiments were generated in rabbits
with purified Sindbis proteins (38).
Protein transport. lodinated staphlococcal protein A as-
says were carried out in a manner similar to that which has
been previously described (4). BSC-40 cells were infected in
24-well dishes with Sindbis, wild-type vaccinia, or vaccinia
VV3S-7 at a multiplicity of 10 PFU per cell. After 4 h of
infection, the medium was removed, the monolayers were
rinsed three times with ice-cold PBS-0.5% bovine serum
albumin (PBS-A) and then placed on ice; 300 pL. of a 1:25
dilution of antiserum in PBS-A was added and allowed to
adsorb at 4°C for 1 h. The monolayers were washed three
times with ice-cold PBS-A; 200 p. of PBS-A containing 1.0 x
106 dpm of '25I-labeled protein A (8 p.Ci/p.g; New England
Nuclear Corp.) was added, and the mixture was incubated at
4°C for 1 h with shaking. The monolayers were then washed
four times with ice-cold PBS-A, solubilized with 1 ml of 2%
SDS at 60°C, and counted in a gamma counter.
Indirect immunoflorescence. Subconfluent monolayers of
BHK-21 cells grown on collagen-coated cover slips were
infected with wild-type vaccinia, VV3S-7, or Sindbis virus at
a multiplicity of 20 PFU per cell. At 8 h postinfection, the
cells were washed twice in PBS and fixed for 2 to 3 min in
PBS containing 2% formaldehyde. After several washes in
TBS (25 mM Tris hydrochloride, 140 mM NaCl, 5 mM KCl,
1.5 mM Na2HPO4, 1 mM CaCI,, 0.5 mM MgCl2, [pH 7.5]),
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cells were incubated for 30 min with Sindbis virus El-
specific monoclonal antibody no. 33 (1/100 dilution of ascites
fluid in TBS plus 1 mg of gelatin per ml) (40) or E2-specific
rabbit immunoglobulin G (IgG) (1/50 dilution of IgG [-5
mg/ml] absorbed against vaccinia-infected BHK monolayers
fixed as described above) (38). After several washes in TBS,
cells were stained with fluorescein-conjugated goat antibod-
ies to mouse or rabbit IgGs for 30 min. The cover slips were
washed with TBS, mounted in 90% glycerol (containing
0.1% phenylene diamine), and viewed with a Leitz phase-
epifluorescence microscope, using a x63 objective.
Phenotypic mixing. Monolayers of chicken embryo fibro-
blasts were infected with wild-type vaccinia or VV3S-7 at a
multiplicity of 10 PFU per cell and labeled with
[35S]methionine. After 12 h, the cells were superinfected
with either Sindbis virus (HR small plaque strain [50]) or SIN
V33/50/23, a Sindbis variant (generously provided by A. L.
Schmaljohn) derived from Sindbis strain AR339 by sequen-
tial selection with three different epitope-specific neutraliz-
ing monoclonal antibodies; no. 33 (El specific), no. 50 (E2
specific), and no. 23 (E2 specific). No. 33 and 50 react with
the HR small plaque strain. Sindbis virus was harvested after
an additional 15 h and purified by both sedimentation veloc-
ity and isopycnic centrifugation (36). Immunoprecipitations
were done essentially as previously described except that
buffers lacked detergent (38). Two microliters of mouse
ascites fluid and 104 to 105 PFU of virus were used for each
sample. Washed immunoprecipitates were suspended and
quantitated by liquid scintillation counting, and the immu-
noprecipitation supernatants were assayed for infectivity.
RESULTS
Construction of the vaccinia-Sindbis structural region re-
combination plasmid. The plasmid pGS20 is a vaccinia virus
insertion vector that has been used to construct a number of
vaccinia recombinants (26, 48). The construction of a mod-
ified insertion plasmid, pVV3, and the recombinant plasmid
containing a complete copy of the cDNA corresponding to
Sindbis 26S RNA is described in the legend to Fig. 1. The
vaccinia-specific sequences in pGS20 from the HindIII site
to the XhoI site, which include the 7.5K vaccinia promoter
(which drives expression of foreign inserts), were trans-
ferred to a smaller ampicillin-resistant pBR322 derivative.
Subsequent modifications included destruction of the ClaI
site in the vaccinia tk gene, insertion of a new ClaI site
replacing the BamHI site downstream from the 7.5K pro-
moter, and insertion of a small polylinker region containing
a unique SacI site. The final hybrid recombination plasmid,
pVV3S, has the 4.2-kilobase (kb) Sindbis virus 26S cDNA
inserted directionally into pVV3 such that the 5' end of the
26S cDNA was proximal to the vaccinia promoter. This
transcriptional unit in turn is flanked by vaccinia virus DNA
sequences containing the 5' and 3' ends of the vaccinia tk
gene.
Isolation of a vaccinia recombinant containing Sindbis
cDNA. The hybrid insertion plasmid, designated as pVV3S,
was coprecipitated with wild-type vaccinia DNA and carrier
salmon sperm DNA by the calcium orthophosphate method
and adsorbed to vaccinia-infected LTK- cells at 3 h postin-
fection. The monolayers were shocked 4 h later with glycerol
for 40 s to facilitate DNA uptake, and the infection was then
allowed to proceed for 48 h. Recombinant viruses, which
should possess a TK- phenotype by virtue of insertional
inactivation of the viral thymidine kinase gene, were ampli-
fied by a low-multiplicity passage through LTK- cells in the
presence of bromodeoxyuridine. Plaque hybridization was
then used to distinguish recombinants from spontaneous
TK- vaccinia mutants; nick-translated Sindbis 26S cDNA
was used as a probe (56). Wild-type vaccinia virus plaques
gave no signal, whereas a large number of strongly hybrid-
izing plaques were obvious in the VV3S population. Individ-
ual positive plaques were recovered by punching out the
corresponding regions from a replica nitrocellulose filter and
subjected to at least two cycles of plaque purification until
each isolate scored as 100% positive in the plaque hybrid-
ization assay. One of the putative positive vaccinia-Sindbis
recombinants, VV3S-7, was used for further experiments.
Genomic structure of VV3S-7. The structure of the genome
of vaccina recombinant VV3S-7 was probed by restriction
mapping and blot analysis (49). At the bottom of Fig. 2 is
drawn the Sail M region from wild-type vaccinia DNA
which contains the HindIll J fragment and the tk gene.
Below that is the DNA structure of the desired recombinant
with the 4.2-kb Sindbis cDNA, flanked by the 7.5K promoter
and polylinker sequences, residing within the vaccinia tk
gene. In such a recombinant, the 4.8-kb HindIII J fragment
would be displaced to 9.2 kb, and the 5.4-kb Sall M fragment
would be replaced by four fragments having sizes of 5, 2.3,
1.5, and 1.3 kb (8, 51). As expected, the 4.8-kb HindIll J
band disappeared in VV3S-7 and a new band appeared at 9.2
kb. Similarly, the Sall M fragment of VV3S-7 was replaced
by four smaller fragments. The DNA from the agarose gel
was then transferred to nitrocellulose and probed with either
32P-labeled HindIII-J DNA or Sindbis 26S cDNA. These
results confirm that the new 9.2-kb HindIII band in VV3S-7
DNA contains J sequences and indicate that the 5- and
1.3-kb SailI bands also contain vaccinia sequences. The
Sindbis probe did not hybridize to wild-type vaccinia DNA
but did hybridize to the 9.2-kb HindIII fragment as well as to
the 5-, 2.3-, and 1.5-kb SailI fragments from VV3S-7.
Transcription of Sindbis sequences. BSC-40 cells were
infected with vaccinia recombinant VV3S-7 in the presence
of cycloheximide (100 ,ug/ml) to amplify early mRNA se-
quences. At 5 h postinfection, the cytoplasmic RNA was
extracted and purified, and the poly(A)+ fraction was ob-
tained by oligo(dT)-cellulose chromatography. This RNA
was fractionated by electrophoresis on denaturing formalde-
hyde gels, transferred to nitrocellulose, and subjected to
Northern blot analyses with nick-translated pVV3S as a
probe. A 4.7-kb RNA which was transcribed from the
vaccinia recombinant hybridized to the probe (Fig. 3, right
side). The left side of Fig. 3 shows 26S RNA (4.1 kb) and
virion RNA (11.7 kb) from Sindbis-infected cells. These
results are consistent with proper transcription of the entire
Sindbis insert including the poly(A) tract and termination at
the tk early transcription-termination region (58). A faint
band in the poly(A)- fraction was detected at about 4.1 kb
(data not shown), suggesting that some premature transcrip-
tion termination may occur near the 3' end of the Sindbis
insert, perhaps at the poly(dA) tail of approximately 35
nucleotides derived during cDNA cloning of the Sindbis
RNA.
To determine the 5' end of the VV3S-7 Sindbis-specific
transcripts nuclease S1 mapping procedures were used (Fig.
4). RNA was obtained from cells at 4 h postinfection, which
in cells permissive for vaccinia replication corresponds to
the period during shift from early to late gene expression.
These results show that the Sindbis transcripts, in cells
permissive for vaccinia replication (BSC-40 and BHK cells),
are being initiated at two distinct sites within the 7.5K
promoter region. This is in agreement with data demonstrat-
ing two RNA start sites in the 7.5K transcription unit as well
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FIG. 1. Construction of pVV3S recombination plasmid. pGS20 was digested with XhoI, filled in using the Klenow fragment, digested with
HindlIl, and the 1.8-kb fragment containing the 7.5K promoter and tk coding region was ligated to pMT21 (a 1.9-kb ampicillin-resistant
pBR322 derivative from Henry V. Huang) which had been digested with HindlIl and SmaI. The resulting plasmid, pVV1, was digested with
Clal, filled in with Klenow, and reclosed, giving rise to pVV2, which therefore lacks a Clal site. The BamHI site of pVV2 was converted to
a Clal site by insertion of Clal linkers, and the polylinker region from pSVC2 (C. Rice, unpublished) containing sites for Clal, HindllI, XbaI,
BglII, Pstl, and Sacl was inserted by directional cloning into the Clal and SmaI sites of the modified pVV2 (the blunt end of the polylinker
fragment was generated by using an Ahalll site -70 nucleotides from the Sacl site). This plasmid is designated pVV3. The Sindbis cDNA
insert was derived by partial AvaIl digestion of a plasmid containing the 3'-terminal 5.5 kb of the Sindbis genome, including poly(A) (51; C.
Rice, unpublished data) and insertion of Clal linkers. A plasmid containing the Clal site immediately adjacent to the sequences corresponding
to the start of 26S RNA was designated pSVS.18. This construct was digested with Clal and Sacl [a unique Sacl site immediately follows
the Sindbis 3'-terminal poly(A) tail] and the 26S cDNA fragment was ligated into the corresponding sites in pVV3. Vaccinia DNA sequences
are designated by bold lines, the vaccinia 7.5K promoter is shown as an open box.
as in a chimeric 7.5K chloramphenicol acetyltransferase
gene (6); the downstream promoter is utilized early in
infection (26, 55), and the other (approximately 55 nucleo-
tides upstream) is used late in infection. Thus, the transcrip-
tion of Sindbis sequences is essentially constitutive during a
VV3S-7 infection of permissive cells. In MDBK and CHO
cells which are nonpermissive for vaccinia replication (16),
the Sindbis-specific transcripts were still produced but were
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FIG. 2. Analysis of VV3S-7 genome structure. Viral DNA was extracted and purified from monolayers of cells infected with wild-type
vaccinia virus (VV) or VV3S-7 (3S). The DNA was digested with restriction endonucleases, fragments were resolved by agarose gel
electrophoresis (ethidium bromide-stained pattern is shown in panel A), and Southern blot analyses were carried out from either vaccinia virus
nick-translated probes HindIII-J DNA (B) or Sindbis 26S cDNA (C). Size markers from a A Hindlll digest (shown at the right) are 23.1, 9.4,
6.6, 4.4, 2.3, and 2.0 kb. The predicted genomic structures of the SalI-M region of wild-type and recombinant vaccinia are diagrammed below.
derived exclusively from the early 7.5K transcription start
(Fig. 4). The VV3S-7 Sindbis transcripts have not yet been
analyzed to determine if they possess unique or heteroge-
neous 3' ends, although the sharp band seen in Fig. 3
indicates that some of the transcripts terminate within a
limited region if not at a unique point.
Expression of Sindbis proteins. To determine what protein
products were translated in vivo from the Sindbis-specific
transcripts, BSC-40 cells infected with wild-type vaccinia
virus, vaccinia recombinant VV3S-7, or Sindbis virus were
labeled with [35S]methionine. The radioactively labeled
proteins were immunoprecipitated with heterospecific anti-
Sindbis antisera as well as with monospecific antisera
directed against the Sindbis El, E2, or C protein. The
precipitated proteins were separated by electrophoresis on
SDS-polyacrylamide gels (Fig. 5). In Sindbis-infected cells
(Fig. 5, right side) the heterospecific Sindbis-specific anti-
serum precipitates precursor glycoprotein PE2, glycopro-
teins El and E2, and capsid protein C, as well as trace
amounts of a 108K polyprotein which contains the amino
acid sequences of both PE2 and El. The three monospecific
antisera displayed the expected specificities and the control
preimmune serum did not cause the precipitation of any
labeled protein. None of the antisera reacted specifically
with any proteins from vaccinia-infected cells (Fig. 5, left
side). In cells infected with the vaccinia recombinant
VV3S-7, Sindbis proteins PE2, El, E2, and C were present
(Fig. 5, center lanes). The Sindbis proteins from VV3S-7-
infected cells comigrate with authentic Sindbis proteins,
which suggests that they have been correctly cleaved and
processed. In an attempt to quantitate the amount of
Sindbis-specific proteins synthesized in VV3S-7-infected
cells, radioactive extracts from cells infected with equivalent
multiplicities of VV3S-7 or Sindbis were immunoprecipi-
tated, and the radioactivity was assayed; after 4 or 18 h of
infection, VV3S-7-infected cells appeared to contain im-
munoprecipitable Sindbis proteins at about 10% of the level
observed in Sindbis-infected cells (data not shown).
A number of parameters of VV3S-7 expression of Sindbis
proteins were analyzed by immunoprecipitation and gel
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FIG. 3. Northern blot analysis of in vivo transcripts from the
VV3S-7 Sindbis cDNA insert. The indicated RNAs were extracted
and purified from infected BSC-40 monolayers. The RNAs were
separated on formaldehyde-agarose gels, transferred to nitrocellu-
lose and hybridized to a 26S RNA-specific nick-translated probe.
SV, total Sindbis RNA; VV3S, poly(A)+ RNA from cells infected
with VV3S-7.
electrophoresis (Fig. 6). BSC-40 cells infected with vaccinia
VV3S-7 were continuously labeled with [35S]methionine,
and the accumulation of Sindbis proteins was examined (Fig.
6a). Sindbis proteins were not evident at 1 h postinfection,
but they became evident at 2 h postinfection and continued
to accumulate throughout the 24 h of infection. This would
suggest that the Sindbis proteins are relatively stable in
vaccinia-infected cells. Note that a vaccinia protein that
migrates very close to PE2 and that immunoprecipitates
nonspecifically for unknown reasons is present in the long
labels and complicates the interpretation of the pattern.
A second series of experiments which involved pulse-
labeling is shown in Fig. 6b. Three important features of
VV3S-7 expression of Sindbis proteins are seen. First, the
Sindbis proteins are synthesized throughout the infection
cycle. Second, there appear to be two peaks of expression,
one at 2 h and one later in infection. This may be due to the
shift from early to late transcription by the 7.5K promoter,
but it could involve posttranscriptional processes as well.
Finally, it can be seen that during a pulse no E2 is produced,
but rather the precursor to E2 is present. The pulse-chase
studies shown in Fig. 6c show that PE2 can be chased into
-256
FIG. 4. Si analysis. RNA was isolated at four hours postinfec-
tion from either wild-type vaccinia (VV wt), VV3S-7, or Sindbis
(SV) virus-infected cell monolayers as indicated. Equal proportions
of these samples were annealed with an excess of a 5' end-labeled
probe derived from pVV3S, digested with Si, and protected frag-
ments were denatured and separated on 4% acrylamide-urea se-
quencing gels. For the Sindbis-infected RNA sample, 5% (right lane)
or 10% (left lane) of the protected material was loaded. The probe
was the 1530 nucleotide HindIII-NcoI fragment of pVV3S, 5'
end-labeled at the NcoI site which is 445 nucleotides 3' to the start
of the 26S cDNA insert. Two protected fragments were found in
Sindbis virus-infected cells corresponding to 26S RNA (445 nucle-
otides) and 49S RNA (454 nucleotides). Protected fragments in
VV3S-7-infected cells corrsponded to the early 7.5K promoter start
(504 nucleotides) and, in permissive cells, to the late 7.5K promoter
start (-560 nucleotides, seen only in the VV3S-7-infected BSC-40
and BHK lanes). The sizes of the end-labeled DNA markers (M) are
indicated.
E2. It is interesting to note that PE2-to-E2 processing
kinetics appear to occur at the same rate in Sindbis-and
VV3S-7-infected cells. It also appears (Fig. 6c) that all three
Sindbis proteins turn over in these experiments and that
these proteins are more labile in the VV3S-7-infected cells
sv
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FIG. 5. Expression of Sindbis proteins. Proteins labeled from 3 to 4.5 h postinfection with [35S]methionine (25 puCi/ml in methionine-free
medium) were prepared from vaccinia (VV), VV3S-7, or Sindbis (SV) virus-infected cells and immunoprecipitated with preimmune serum
(PI), heterospecific anti-Sindbis serum (SV), or monospecific antisera directed towards Sindbis envelope (El or E2) or capsid (C) proteins.
The immune precipitates were then subjected to SDS-polyacrylamide gel electrophoresis and autoradiography. Sindbis-specific proteins are
identified in the right margin.
than in Sindbis-infected cells. Note also that the 108K
polyprotein is present in small amounts in Sindbis-infected
cells (where it turns over rapidly) but is not seen in VV3S-
7-infected cells.
We also examined several other cell lines, both permissive
and nonpermissive for vaccinia replication, for the produc-
tion of Sindbis proteins after infection by VV3S-7, and some
of the results are shown in Fig. 6d. CHO, MDBK, BHK, and
chicken embryo fibroblast cells infected with VV3S-7 all
produced the same series of Sindbis proteins as infected
BSC-40 cells. Thus, even in cell lines nonpermissive for
vaccinia growth (CHO and MDBK cells), the expression of
the Sindbis-specific transcripts and protein products is effi-
cient, and proteolytic processing of the polyprotein precur-
sor occurs.
Posttranslational modifications of Sindbis proteins. Sindbis
El and E2 proteins are glycosylated membrane proteins.
The PE2, El, and E2 proteins found after infection with
Sindbis or vaccinia VV3S-7 comigrated in one-dimensional
polyacrylamide gels, which is suggestive evidence for similar
states of glycosylation. Two additional experiments which
support this observation were conducted. First, the effect of
tunicamycin, a drug which inhibits N glycosylation, on
Sindbis and VV3S-7 protein expression was assayed (Fig. 7).
Sindbis or VV3S-7 proteins that were synthesized in either
the presence or the absence of the drug comigrated. The
nonglycosylated forms of PE2 and El, synthesized in the
presence of the drug, comigrated, which implies that the
polypeptide backbones of the Sindbis proteins and the
VV3S-7 proteins are identical. Thus, the fact that the
glycosylated forms of Sindbis and VV3S-7 proteins also
comigrate implies that they are glycosylated in a similar, if
not identical, manner. Second, the VV3S-7-derived PE2, El,
and E2 proteins were shown to be specifically labeled (as
opposed to the capsid protein) with the radioactive sugar
[3H]glucosamine (Fig. 7).
Transport of Sindbis virus proteins. During a Sindbis virus
infection, the virus envelope proteins are core glycosylated
during insertion into the endoplasmic reticulum, and the core
oligosaccharides are modified during the translocation of the
envelope proteins from the site of their synthesis to the cell
surface. The VV3S-7-derived Sindbis proteins appear to be
modified in the same way as are authentic Sindbis proteins,
which implies that these proteins are also being transported
to the cell surface. To assay this directly we used a radioim-
mune assay in which anti-Sindbis antibodies were adsorbed
to the surface of infected cells, followed by incubation with
1251I-labeled protein A from Staphylococcus aureus. The
amount of 125I-labeled protein A bound is a measure of
immunoreactive Sindbis proteins present at the cell surface
(Table 1). Uninfected cells or cells infected with vaccinia
wild-type, vaccinia VV3S-7, or Sindbis virus were adsorbed
with preimmune serum, anti-Sindbis El + E2 antiserum, or
anti-Sindbis C protein antiserum. The anti-capsid antiserum
serves as a partial control for the integrity of the cells. It has
been reported that late in Sindbis infection, the capsid
protein is partially accessible at the cell surface to anti-
capsid antibodies (44), and we did find an increase in binding
of anti-capsid antibody to cells infected with Sindbis virus.
There was no specific binding of antibodies to either
mock-infected or vaccinia wild-type-infected cells. Vaccinia
VV3S-7-infected cells did not react with preimmune serum
but showed significant reactivity with anti-Sindbis El + E2
antiserum, indicating that Sindbis El or E2 or both are
present on the surface. Furthermore, by comparing the
radioactivity bound to these cells with that bound to Sindbis-
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FIG. 6. Kinetics of Sindbis protein expression in VV3S-7-infected cells. Infected or mock-infected BSC-40 cell monolayers were labeled
with [35S]methionine in medium containing 1/10 of the normal concentration of methionine (unless otherwise indicated) according to the
regimens described below. The radioactive proteins were analyzed by immunoprecipitation with polyspecific anti-Sindbis antisera and
followed by SDS-polyacrylamide gel electrophoresis. Sindbis-specific proteins are identified in the right margins. Abbreviations: VV,
wild-type vaccinia; VV3S, recombinant vaccinia VV3S-7; SV, Sindbis virus; M, mock-infected cells. (A) Continuous label. [35S]methionine
was present from the time of infection until the indicated hours postinfection. SV, M, and VV extracts were labeled for 24 h. (B) Pulse-label.
[35S]methionine was added in methionine-free medium for 30 min at the indicated hours postinfection, and then extracts were prepared
immediately. The Sindbis markers were from the continuous labeling experiment. (C) Pulse-chase. Monolayers were pulse-labeled with
[35S]methionine in methionine-free medium for 10 min at 5 h postinfection. The radioactive label was then replaced with medium containing
lOOx methionine (non-radioactive) and 75 ,ug of cycloheximide per ml for the indicated number of minutes. (D) Continuous label in various
cell types. [35S]methionine was present from 2 h postinfection until the preparation of the extracts at 24 h postinfection.
infected cells (Table 1), it would appear that these proteins
are present at 12% the amount found in Sindbis-infected
cells.
In a second experiment, the Sindbis proteins present on
the surface of BHK cells infected by vaccinia VV3S-7 were
visualized by indirect immunofluorescence. At 8 h postin-
fection, the cells were fixed and incubated with either El or
E2 monospecific antibodies (Fig. 8). Although wild-type
vaccinia-infected cells showed a weak and diffuse pattern of
immunofluorescent staining, both El and E2 (or PE2) could
be specifically detected in the surface of VV3S-7-infected
cells. The recombinant-derived glycoproteins had a patchy,
focal appearance over the entire cell surface. This was
similar to the pattern observed for Sindbis virus-infected
cells or cells coinfected with both Sindbis virus and wild-
type vaccinia virus (data not shown), but the VV3S-7-
infected cells had a significantly lower level of fluorescent
staining. Thus, these qualitative levels of immunofluores-
cence are in agreement with the results of the radioimmune
assays mentioned above.
Biological activity of Sindbis proteins. The proteins en-
coded in the 26S cDNA Sindbis insert in vaccinia VV3S-7
have structural, as opposed to enzymatic, functions in the
Sindbis life cycle. We performed several sets of experiments
to determine whether the recombinant-derived polypeptides
are capable of functioning in virus assembly. Preliminary
experiments showed that in mixed infections of Sindbis virus
and vaccinia virus (at high input multiplicities), the time
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FIG. 7. Processing of Sindbis proteins in VV3S-7-infected cells. The left panel shows the effects of carrying out infections in the presence
(+TM) or absence (-TM) of 1 ,ug of tunicamycin per ml. The proteins were continuously labeled for 4 h. The positions of the nonglycosylated
Sindbis virus proteins (PE2* and E1*) are indicated. The right panel shows the results of infections in the presence of [3H]glucosamine. In
both experiments the radioactive proteins were immunoprecipitated with anti-Sindbis antiserum, separated on SDS-polyacrylamide gels, and
fluorographed.
course of Sindbis infection and the yield of infectious virus
were essentially unaffected (data not shown). In addition,
chicken embryo fibroblast cultures which had been infected
with vaccinia virus for 12 h could be superinfected with
Sindbis virus with only a 5- to 10-fold loss in Sindbis yield. A
number of complementation studies were undertaken with
VV3S-7 and various Sindbis RNA' temperature-sensitive
mutants defective in each of the structural protein genes. In
these experiments, we examined the yield of Sindbis virus
(assayed at the permissive temperature) produced from
mixed infections of these mutants and VV3S-7 at the
nonpermissive temperature. Monolayers were either in-
fected with both viruses simultaneously or superinfected
with Sindbis virus after 12 h of vaccinia infection; mixed
infections with wild-type vaccinia virus were used as con-
trols. Under these conditions, no significant increase in the
yield of progeny Sindbis virus was detected in any of the
mixed infections with VV3S-7.
As an alternative approach, we examined the ability of the
vaccinia-encoded Sindbis glycoproteins to be incorporated
into mature Sindbis virions. A number of glycoprotein-
specific monoclonal antibodies capable of neutralizing
Sindbis virus (AR339 strain) have been used to sequentially
TABLE 1. Presence of Sindbis glycoproteins at the infected cell
surfacea
Reactivity (cpm) with the following anti-
Infecting virus serumb
PI aC caEl + aE2
None (Mock infection) 1,090 6,100 3,600
Vaccinia 940 3,600 3,000
VV3S-7 920 4,700 11,800
Sindbis 1,000 31,700 72,200
a lodinated staphylococcal protein A test for the presence of surface
proteins which are reactive with anti-Sindbis antisera.
b PI, preimmune; aLC, anti-Sindbis capsid; otEl + E2, anti-Sindbis El and
E2.
select resistant variants (40; A. L. Schmaljohn, unpublished
data). A triple variant designated SIN V33/50/23, which is
resistant to monoclonal antibody no. 33 (El specific) as well
as monoclonal antibody no. 50 (E2 specific), was used to
superinfect cells which had been previously infected with
either wild-type vaccinia or VV3S-7. The vaccinia-encoded
Sindbis proteins in VV3S-7 were derived from the HR small
plaque strain of Sindbis virus, which reacts with both of
these monoclonal antibodies. The progeny Sindbis virions in
the medium were purified by both sedimentation velocity
and equilibrium density centrifugation and tested by immu-
noprecipitation with the above-mentioned epitope-specific
antisera capable of distinguishing between the Sindbis gly-
coproteins encoded by VV3S-7 and the input Sindbis
virions. The data in Table 2 indicate that VV3S-7-derived
proteins are capable of being incorporated into mature
Sindbis virions which are infectious (as determined by
removal of infectivity from immunoprecipitation superna-
tants and neutralization assays; data not shown) and implies,
but does not rigorously prove, that they are biologically
active. Similar results were obtained in BHK cells (data not
shown). VV3S-7 proteins are incorporated specifically into
Sindbis virions, as neither El, E2, or C could be detected in
mature VV3S-7 virions (data not shown).
DISCUSSION
We have constructed a vaccinia virus recombinant which
contains a complete cDNA copy of Sindbis virus 26S RNA
inserted into the vaccinia tk gene. This insert is expressed as
a 4.7-kb poly(A)+ transcript which is translated into Sindbis
PE2, El, E2, and C proteins which are correctly cleaved,
glycosylated, and transported. This demonstrates that the
26S sequences specify all the necessary catalytic activities or
recognition signals required to ensure the proper synthesis
and maturation of the encoded polypeptides. A similar
conclusion was reached by Huth et al. (19), who
microinjected the 26S mRNA of Semliki Forest virus into
Xenopus oocytes and found that the capsid protein and the
glycoproteins were formed and that the glycoproteins were
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FIG. 8. Immunofluorescence microscopy of VV3S-7-infected cells. BHK cells infected for 8 h with either wild-type vaccinia virus (WT),
VV3S-7 (3S), or Sindbis virus (SV) were fixed, incubated with El-specific (aEl) or E2-specific (oxE2) antibodies and stained with
fluorescein-conjugated goat antisera as described in the Methods section. Immunofluorescence photographs are shown for all of these samples
with phase contrast photographs included for wild-type vaccinia-infected cells only.
transported to the plasma membrane. We have also shown
here that the Sindbis proteins produced from the vaccinia
recombinant are incorporated into infectious virions in cells
coinfected with antigenically distinguishable Sindbis virus,
implying that these proteins are biologically active.
The processing of the alphavirus structural proteins re-
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TABLE 2. Incorporation of vaccinia-encoded Sindbis
glycoproteins into infectious Sindbis virus'
% of Sindbis progeny
reacting with the following
Mixed infection antiserumb
Nonimmune No. 33 No. 50
Sin V33/50/23 plus wild-type vaccinia 1 1 2
Sin V33/50/23 plus VV3S-7 2 32 56
Sin HRsp plus wild-type vaccinia 0 85 78
a See the text for experimental protocol.
b Expressed as percent of input cpm.
quires several proteolytic cleavages. The results presented
here as well as earlier results show that these cleavages can
occur in the absence of viral RNA replication or expression
of the nonstructural proteins; thus, nonstructural proteases
or virus nucleocapsids are not required for processing of the
structural proteins. The cleavage of the capsid protein from
the nascent polyprotein precursor is believed to be catalyzed
by an autoproteolytic activity that resides within the capsid
protein itself (1, 13, 41, 43). The two cleavages that separate
PE2 and El from one another (and give rise to a small
polypeptide, termed 6K protein, encoded between PE2 and
El [59]) may be catalyzed by signalase (37). Such a mode of
cleavage would imply that the C terminus of PE2 is found in
the lumen of the rough endoplasmic reticulum, at least
transiently, for signalase is known to be active only on the
lumenal sides of the endoplasmic reticulum and not within
the cytoplasm. Both cleavages occur after alanine, one of the
preferred substrates for signalase. If, alternatively, the C
terminus of PE2 is cytoplasmic, cleavage must be catalyzed
by a currently unknown protease, which we believe unlikely,
or by a virus protease present in the structural protein
domain, of which the only one known at present is the capsid
protease. The last cleavage in the processing of the
alphavirus structural proteins, that of PE2 to E2 and E3 (20,
29, 59), has been postulated to be catalyzed by a Golgi
protease during transit to the plasma membrane (9, 37). The
expression experiments reported here as well as other ex-
pression experiments using Semliki Forest virus (19) show
that this processing can occur in the absence of virus
budding.
Previous attempts to express cloned copies of alphavirus
26S RNA have used DNA copies under the control of simian
virus 40 promoters microinjected into nuclei (10, 22, 23). In
one construction, incorrect splicing apparently led to incor-
rect processing and transport of one of the glycoproteins,
whereas a second construction gave correct processing and
transport. We have also attempted to use simian virus 40
promoters in an attempt to express Sindbis genes with
unsatisfactory results (C. M. Rice, unpublished data). The
use of vaccinia virus as a vector obviates the difficulties
encountered by spurious splicing, since replication occurs in
the cytoplasm. In addition, the use of an infectious vaccinia
recombinant to express alphavirus genes has the obvious
advantage that large numbers of diverse cell types can be
synchronously infected with virtually 100% efficiency, a
result that cannot be achieved by microinjection or calcium
phosphate uptake of DNA. Finally, the biology of vaccinia
and that of alphaviruses are compatible, allowing
alphaviruses to replicate to high titers in cells infected with
vaccinia. On the other hand, because both viruses possess a
rather wide host range, cells can be chosen in which one
virus will replicate well while being refractory to the repli-
cation of the other virus. Thus, this system of alphavirus
gene expression is flexible and can be adapted to the
purposes of the particular experiment.
The experiments demonstrating incorporation of the vac-
cinia-encoded Sindbis proteins into virions in mixedly in-
fected cells imply that these proteins are properly processed
and transported and possess biological activity. Unfortu-
nately, we were unable to demonstrate complementation of
VV3S-7 with RNA' ts mutants as a more stringent test of
biological activity. This indicates either that the Sindbis
cDNA clone used in this study is defective, which seems
unlikely in view of the data presented here as well as
extensive nucleotide sequence analysis (51), or, more likely,
that the vaccinia recombinant may express insufficient quan-
tities of alphavirus structural proteins to rigorously demon-
strate their activity by complementation. In this event, it
may be possible to obtain complementation by developing
vaccinia expression systems that utilize more efficient pro-
moters. In any event, this system is ideally suited to the use
of site-specific mutagenesis to study the processing, trans-
port, and immunogenicity of alphavirus glycoproteins. Im-
provements in the methodology for isolation of recombinant
viruses, further characterization of vaccinia promoters and
transcription termination signals, and development of rapid
transient expression assays for preliminary analysis of re-
combinant plasmid constructions would greatly facilitate the
use of vaccinia for such studies. These areas are currently
being pursued in this and other laboratories.
Finally, the use of vaccinia virus to express foreign virus
genes for potential vaccine development is under investiga-
tion in a number of laboratories. The results here show that
vaccinia is also potentially useful for the development of
vaccines against alphaviruses. Studies to test the efficiency
of the recombinant VV3S-7 in producing immunity to
Sindbis virus in experimental animals are under way.
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